Holen Sie sich die Stockscreener-App
6.62
0.62%
-0.010
Schlusskurs vom Vortag:
$6.61
Offen:
$6.55
24-Stunden-Volumen:
400.72K
Relative Volume:
0.06
Marktkapitalisierung:
$2.32B
Einnahmen:
$143.05M
Nettoeinkommen (Verlust:
$-145.99M
KGV:
-15.46
EPS:
-0.4282
Netto-Cashflow:
$-134.06M
1W Leistung:
-5.21%
1M Leistung:
-0.47%
6M Leistung:
+38.88%
1J Leistung:
+96.08%
1-Tages-Spanne:
$6.52
$6.715
1-Wochen-Bereich:
$6.52
$7.1301
52-Wochen-Spanne:
$2.99
$9.75
Nuvation Bio Inc Stock (NUVB) Company Profile
Firmenname
Nuvation Bio Inc
Sektor
Branche
Telefon
332-208-6102
Adresse
1500 BROADWAY, NEW YORK
Compare NUVB vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NUVB
Nuvation Bio Inc
|
6.61 | 2.32B | 143.05M | -145.99M | -134.06M | -0.4282 |
VRTX
Vertex Pharmaceuticals Inc
|
522.04 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
799.73 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,000.06 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.54 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.27 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-11-19 | Eingeleitet | B. Riley Securities | Buy |
| 2025-09-30 | Eingeleitet | Jefferies | Buy |
| 2025-04-23 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2024-03-27 | Hochstufung | Jefferies | Hold → Buy |
| 2024-03-26 | Hochstufung | BTIG Research | Neutral → Buy |
| 2023-01-06 | Herabstufung | Jefferies | Buy → Hold |
| 2022-08-02 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-08-02 | Herabstufung | BTIG Research | Buy → Neutral |
| 2022-05-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-04-06 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-03-08 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-03-08 | Eingeleitet | BTIG Research | Buy |
| 2021-03-08 | Eingeleitet | Cowen | Outperform |
| 2021-03-08 | Eingeleitet | Jefferies | Buy |
| 2021-03-08 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Nuvation Bio Inc Aktie (NUVB) Neueste Nachrichten
Jim Cramer sends strong 5-word message on surging biotech stock - Yahoo Finance
Jim Cramer: This Health Care Stock Is Pure Spec, The Only Neocloud I Like Is... - Benzinga
Does Nuvation Bio (NUVB) Have the Potential to Rally 91.92% as Wall Street Analysts Expect? - Yahoo Finance
Nuvation Bio to Participate in Upcoming Investor Conferences - Investing News Network
Nuvation Bio (NUVB) Upgraded to Buy: Here's Why - Yahoo Finance
Nuvation Bio downgraded to Hold after 200% rall... - Pluang
NUVB|Nuvation Bio Inc|Price:7.100|Chg%:+0.340 - TradingKey
Nuvation Bio | 4: Statement of changes in beneficial ownership of securities-Officer Hattersley Gary - Moomoo
Nuvation Bio (NUVB) CSO sells 100K shares at $7.09 - Stock Titan
Nuvation Bio stock rises after Cantor starts at Overweight - Investing.com
Why is Nuvation Bio stock rallying today? By Investing.com - Investing.com Canada
Nuvation Bio rises as Cantor initiates at overweight - Seeking Alpha
Cantor Fitzgerald initiates Nuvation Bio stock with overweight rating - Investing.com
Cantor Fitzgerald initiates Nuvation Bio stock with overweight rating By Investing.com - Investing.com India
Why is Nuvation Bio stock rallying today? - Investing.com
JPMorgan sees 100% upside in overlooked cancer drug stock - thestreet.com
FDA grants Nuvation fast-track status for safusidenib in IDH1-mutant glioma - AllSci
Nuvation Bio receives FDA fast track status for brain cancer drug - Investing.com South Africa
Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma - PR Newswire
Market Sentiment Around Loss-Making Nuvation Bio Inc. (NYSE:NUVB) - Moomoo
One NYSEListed Biotechnology Stock at Resistance Level – NUVB - kalkine.ca
Nuvation (NUVB) Results Breakdown: EPS Comes in Above Forecast for the Current Session; Share Response - Vinanet
Nuvation Bio Inc (NUVB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - tradingkey.com
This cancer drug stock could double as its treatment hits the market, JPMorgan says - CNBC
Nuvation wins new Overweight at J.P. Morgan (NUVB:NYSE) - Seeking Alpha
Wall Street Analysts Predict a 105.71% Upside in Nuvation Bio (NUVB): Here's What You Should Know - Yahoo Finance
NUVB Stock Is Soaring Today — Why RBC Sees $3B Opportunity In Nuvation Bio's Brain Cancer Drug - Stocktwits
JPMorgan Initiates Nuvation Bio at Overweight With $13 Price Target - marketscreener.com
JPMorgan initiates Nuvation Bio stock coverage with overweight rating By Investing.com - Investing.com South Africa
JPMorgan initiates Nuvation Bio stock coverage with overweight rating - Investing.com
The Manufacturers Life Insurance Company Reduces Stake in Nuvation Bio Inc. $NUVB - marketbeat.com
Nuvation Bio (NUVB) Is Down 5.8% After Wider Q2 Loss Despite Surging Revenue And IBTROZI Focus - simplywall.st
Nuvation Bio (NUVB) Q2 2026 Earnings Call Transcript - The Globe and Mail
Nuvation Bio (NUVB) Could Be 69% Undervalued On Earnings And IBTROZI Data Focus - Sahm
Brokers Set Expectations for Nuvation Bio FY2026 Earnings - MarketBeat
Nuvation Bio Inc. (NYSE:NUVB) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
559,180 Shares in Nuvation Bio Inc. $NUVB Bought by Renaissance Technologies LLC - marketbeat.com
Power Solutions International And 2 More Growth Stocks With Strong Insider Ownership - simplywall.st
HC Wainwright Predicts Nuvation Bio Q1 Earnings - MarketBeat
Nuvation Bio Q2 Earnings Call Highlights - marketbeat.com
Nuvation Bio Inc (NUVB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
A Quick Look at Today's Ratings for Nuvation Bio(NUVB.US), With a Forecast Between $12 to $21 - moomoo.com
Truist Financial Maintains Nuvation Bio(NUVB.US) With Buy Rating, Announces Target Price $13 - Moomoo
RBC Adjusts PT on Nuvation Bio to $20 From $19, Maintains Outperform Speculative Risk Rating - marketscreener.com
Why Nuvation Bio (NUVB) Is Down 8.8% After Surging Q2 2026 Revenue and IBTROZI Data Tease - simplywall.st
NUVB SWOT Analysis: Revenue Surge Amidst Ongoing Losses Revealed in 10-Q Filing - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Encourages Nuvation Bio Inc - The National Law Review
Earnings call transcript: Nuvation Bio tops revenue forecasts in Q2 2026 - Investing.com Nigeria
Nuvation Bio (NYSE:NUVB) Announces Quarterly Earnings Results - MarketBeat
Nuvation Bio Inc. Stock 12‑Month Price Target Raised to $12.89, Implies 102% Upside - TradingView
Nuvation Bio earnings missed by $0.03, revenue topped estimates - Investing.com
Finanzdaten der Nuvation Bio Inc-Aktie (NUVB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.72%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):